Publications by authors named "Romain Roth"
Background: Antibiotic therapy alone is unable to control recurrent urinary tract infection (UTI); uropathogens have become multiresistant, and alternative strategies are needed. Far from sterile, the urinary tract contains various low-biomass microbiota, some of whose members appear to protect against clinical UTI.
Objectives: This narrative review summarizes (a) the current knowledge of male and female urobiomes in healthy and diseased states, as well as their interplay among sexual partners and (b) clinical trials to date assessing probiotic and other nonantibiotic measures to reduce UTI.
Background: Limited data exist to describe end-of-treatment (EOT) parameters of antifungal therapy for invasive mould infections (IMI).
Methods: In a 10-year cohort of consecutive adult allogeneic haematopoietic cell transplant recipients with proven/probable IMI, we describe treatment duration and patient profile at EOT.
Results: There were 61 patients with 66 proven/probable IMI identified: 47/66 (71%) invasive aspergillosis (IA), 11/66 (17%) mucormycosis, and 8/66 (12%) other-IMI.
Background: Despite progress in diagnostic, prevention, and treatment strategies, invasive mold infections (IMIs) remain the leading cause of mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients.
Methods: We describe the incidence, risk factors, and mortality of allo-HCT recipients with proven/probable IMI in a retrospective single-center 10-year (01/01/2010-01/01/2020) cohort study.
Results: Among 515 allo-HCT recipients, 48 (9.
Background: Antifungal treatment duration and changes for invasive mould infections (IMI) have been poorly described.
Methods: We performed a 10-year cohort study of adult (≥18-year-old) allogeneic haematopoietic cell transplant recipients with proven/probable IMI to describe the duration and changes of antifungal treatment. All-cause-12-week mortality was described.
Article Synopsis
- The study analyzed antifungal combination therapy used for invasive mold infections (IMIs) in patients who underwent allogeneic hematopoietic cell transplantation (HCT) over a 10-year period.
- Out of 515 patients, 9.1% experienced 48 IMI episodes, primarily invasive aspergillosis and non-IA IMIs, with almost half receiving some form of combination antifungal treatment.
- Significant mortality was observed, with a 30% death rate at 12 weeks, and patients treated mainly with combination therapy had an increased risk of mortality, especially those with non-IA IMIs.